GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (FRA:3XV) » Definitions » Enterprise Value

Xvivo Perfusion AB (FRA:3XV) Enterprise Value : €1,018.72 Mil (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xvivo Perfusion AB's Enterprise Value is €1,018.72 Mil. Xvivo Perfusion AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €9.19 Mil. Therefore, Xvivo Perfusion AB's EV-to-EBIT ratio for today is 110.81.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Xvivo Perfusion AB's Enterprise Value is €1,018.72 Mil. Xvivo Perfusion AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €9.19 Mil. Therefore, Xvivo Perfusion AB's EV-to-EBITDA ratio for today is 110.81.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Xvivo Perfusion AB's Enterprise Value is €1,018.72 Mil. Xvivo Perfusion AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €56.00 Mil. Therefore, Xvivo Perfusion AB's EV-to-Revenue ratio for today is 18.19.


Xvivo Perfusion AB Enterprise Value Historical Data

The historical data trend for Xvivo Perfusion AB's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Enterprise Value Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 834.64 741.98 473.12 881.68

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 634.94 732.17 703.19 881.68 702.53

Competitive Comparison of Xvivo Perfusion AB's Enterprise Value

For the Medical Devices subindustry, Xvivo Perfusion AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Enterprise Value falls into.



Xvivo Perfusion AB Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Xvivo Perfusion AB's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Xvivo Perfusion AB's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (FRA:3XV) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Xvivo Perfusion AB's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1018.722/9.193
=110.81

Xvivo Perfusion AB's current Enterprise Value is €1,018.72 Mil.
Xvivo Perfusion AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.19 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Xvivo Perfusion AB's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1018.722/9.193
=110.81

Xvivo Perfusion AB's current Enterprise Value is €1,018.72 Mil.
Xvivo Perfusion AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.19 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Xvivo Perfusion AB's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1018.722/56.002
=18.19

Xvivo Perfusion AB's current Enterprise Value is €1,018.72 Mil.
Xvivo Perfusion AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €56.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB Enterprise Value Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (FRA:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (FRA:3XV) Headlines

No Headlines